CANCER RESEARCH-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214370, encodeId=4ecd12143e049, content=投稿命中率:95.0 经验分享：2255, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=978b6414011, createdName=ms1000001245672662, createdTime=Tue Apr 26 00:56:18 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189532, encodeId=08ba118953229, content=虎年大吉，虎虎生威啊!今年来一篇!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Tue Feb 01 11:39:26 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享： Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=)]

2023-02-11 osmataku 来自北京

好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段

92 0

[GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214370, encodeId=4ecd12143e049, content=投稿命中率:95.0 经验分享：2255, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=978b6414011, createdName=ms1000001245672662, createdTime=Tue Apr 26 00:56:18 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189532, encodeId=08ba118953229, content=虎年大吉，虎虎生威啊!今年来一篇!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Tue Feb 01 11:39:26 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享： Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=)]

2023-01-04 wawljwalj9232 来自福建省

偏重的研究方向：癌症研究;肿瘤;EMT
经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊

99 0

[GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214370, encodeId=4ecd12143e049, content=投稿命中率:95.0 经验分享：2255, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=978b6414011, createdName=ms1000001245672662, createdTime=Tue Apr 26 00:56:18 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189532, encodeId=08ba118953229, content=虎年大吉，虎虎生威啊!今年来一篇!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Tue Feb 01 11:39:26 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享： Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=)]

2022-11-20 slientwo

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤研究
经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。

160 0

[GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214370, encodeId=4ecd12143e049, content=投稿命中率:95.0 经验分享：2255, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=978b6414011, createdName=ms1000001245672662, createdTime=Tue Apr 26 00:56:18 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189532, encodeId=08ba118953229, content=虎年大吉，虎虎生威啊!今年来一篇!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Tue Feb 01 11:39:26 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享： Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=)]

2022-10-19 duanbiao127

为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢

57 0

[GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214370, encodeId=4ecd12143e049, content=投稿命中率:95.0 经验分享：2255, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=978b6414011, createdName=ms1000001245672662, createdTime=Tue Apr 26 00:56:18 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189532, encodeId=08ba118953229, content=虎年大吉，虎虎生威啊!今年来一篇!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Tue Feb 01 11:39:26 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享： Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=)]

2022-10-02 鸡爪

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？

52 0

[GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214370, encodeId=4ecd12143e049, content=投稿命中率:95.0 经验分享：2255, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=978b6414011, createdName=ms1000001245672662, createdTime=Tue Apr 26 00:56:18 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189532, encodeId=08ba118953229, content=虎年大吉，虎虎生威啊!今年来一篇!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Tue Feb 01 11:39:26 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享： Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=)]

2022-04-26 ms1000001245672662

投稿命中率:95.0
经验分享：2255

88 0

[GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214370, encodeId=4ecd12143e049, content=投稿命中率:95.0 经验分享：2255, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=978b6414011, createdName=ms1000001245672662, createdTime=Tue Apr 26 00:56:18 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189532, encodeId=08ba118953229, content=虎年大吉，虎虎生威啊!今年来一篇!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Tue Feb 01 11:39:26 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享： Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=)]

2022-02-01 Tou gao小菜鸡

虎年大吉，虎虎生威啊!今年来一篇!

38 0

[GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214370, encodeId=4ecd12143e049, content=投稿命中率:95.0 经验分享：2255, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=978b6414011, createdName=ms1000001245672662, createdTime=Tue Apr 26 00:56:18 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189532, encodeId=08ba118953229, content=虎年大吉，虎虎生威啊!今年来一篇!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Tue Feb 01 11:39:26 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享： Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=)]

2021-08-25 PILIXIA

这个杂志是不是一般都会送外审

47 0

[GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214370, encodeId=4ecd12143e049, content=投稿命中率:95.0 经验分享：2255, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=978b6414011, createdName=ms1000001245672662, createdTime=Tue Apr 26 00:56:18 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189532, encodeId=08ba118953229, content=虎年大吉，虎虎生威啊!今年来一篇!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Tue Feb 01 11:39:26 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享： Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=)]

2021-08-25 PILIXIA

eeeeeee

43 0

[GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2101656, encodeId=eba121016568d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：是肿瘤领域非常老牌的杂志，创刊也有80年了，在业内非常认可，是AACR旗下第一个期刊，偏向于接收基础类的文章。需要把故事讲的富有逻辑且新颖，更看重机制的探讨，也需要相应的临床数据作支撑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Nov 20 20:27:32 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094678, encodeId=edde20946e829, content=为啥刚投稿后，每天都会被暂停呀？每天都要重新确认投递呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=73462303137, createdName=duanbiao127, createdTime=Wed Oct 19 10:40:14 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091472, encodeId=58fc20914e26f, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问如果送外审了，大概多久会收到消息啊？一般拒稿多还是大修多？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=96225514779, createdName=鸡爪, createdTime=Sun Oct 02 14:16:17 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214370, encodeId=4ecd12143e049, content=投稿命中率:95.0 经验分享：2255, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=978b6414011, createdName=ms1000001245672662, createdTime=Tue Apr 26 00:56:18 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189532, encodeId=08ba118953229, content=虎年大吉，虎虎生威啊!今年来一篇!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Tue Feb 01 11:39:26 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享： Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=)]

2020-07-28 silent111

审稿速度:1.0 | 投稿命中率:25.0
经验分享：
Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？

125 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务